Loading
A phase 2 trial of ABBV-706, Atezolizumab, Etoposide in small-cell lung cancer, run by AbbVie, now recruiting.
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07155174 by AbbVie, with 180 participants planned, started 2025-11-25 and due to reach its primary completion in 2029-04. Interventions recorded: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Carboplatin. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/